polaris venture management co v llc  insider stock trading  openinsider sector all sectors group by sector aerospace agriculture automobile building business services chemical electrical energy fashion financial food  beverage fund healthcare household insurance machinery media metals mining other personal services real estate retail technology telecom transportation utility industry all industries group by industry insiders filings all purchases sales cik   address one marina park drive th fl boston ma   results links secyahoogooglefinviztradingviewstockchartsstocktwitsdownload csv tc stat stk ins fil d w m q h y avg pretpwinssretswins filing date t date ticker issuerinc sector indindustry owner ost rel title t tval price l qty oc own h ry ry rm rm rw rw rd rd fd fw fm fm fm fy  selbselecta biosciences incdehealthdrugpharmaceutical preparationspolaris venture management co v llcmatpdi  gncagenocea biosciences incdehealthbioprdbiological products no diagpolaris venture management co v llcmatsmi  gncagenocea biosciences incdehealthbioprdbiological products no diagpolaris venture management co v llcmatsmi  oculocular therapeutix incdehealthdrugpharmaceutical preparationspolaris venture management co v llcmatsi  trvntrevena incdehealthdrugpharmaceutical preparationspolaris venture management co v llcmatsi  trvntrevena incdehealthdrugpharmaceutical preparationspolaris venture management co v llcmatsi  gncagenocea biosciences incdehealthbioprdbiological products no diagpolaris venture management co v llcmatsmi  gncagenocea biosciences incdehealthbioprdbiological products no diagpolaris venture management co v llcmatsmi  cerucerulean pharma incdehealthdrugpharmaceutical preparationspolaris venture management co v llcmatpdi  gncagenocea biosciences incdehealthbioprdbiological products no diagpolaris venture management co v llcmatpdi  trvntrevena incdehealthdrugpharmaceutical preparationspolaris venture management co v llcmatpdi  fatefate therapeutics incdehealthbioprdbiological products no diagpolaris venture management co v llcmatpdi  bindbind therapeutics incdehealthdrugpharmaceutical preparationspolaris venture management co v llcmatpdi dderivative transaction in filing usually option exercise mmultiple transactions in filing earliest reported transaction date and weighted average transaction price aamended filing eerror detected in filing s  salesale of securities on an exchange or to another person s  saleoesale of securities on an exchange or to another person after option exercise f  taxpayment of exercise price or tax liability using portion of securities received from the company p  purchasepurchase of securities on an exchange or from another person return to top contact copyright   openinsidercom all rights reserved ﻿ polaris venture management co v llc decreases position in ocular therapeutix inc ocul  chaffey breeze daily ratings  news for ocular therapeutix inc complete the form below to receive the latest headlines and analysts recommendationsfor ocular therapeutix inc with our free daily email newsletter follow chaffeybreeze recent posts biogen inc nasdaqbiib shares sold by highvista strategies llc evercore isi reaffirms “outperform” rating for cardinal health inc nysecah orion energy systems nasdaqoesx given daily media sentiment rating of  contrasting surmodics srdx and h b fuller ful tech data corporation tecd versus pcm pcmi headtohead survey lexicon pharmaceuticals inc lxrx stock rating lowered by zacks investment research schnitzer steel industries nasdaqschn getting favorable news coverage study shows lumber liquidators holdings inc ll upgraded at zacks investment research zacks investment research upgrades libbey inc lby to hold commercial metals company cmc receives consensus recommendation of “hold” from brokerages consolidated communications holdings inc cnsl receives average rating of “hold” from brokerages visionary asset management inc buys shares of  powershares qqq trust series  nasdaqqqq lowe’s companies inc nyselow shares bought by diversified trust co new capital management lp continues to hold stake in powershares qqq trust series  qqq zacks investment research upgrades fmc corporation nysefmc to buy altra industrial motion corp nasdaqaimc downgraded to hold at zacks investment research irhythm tech irtc cut to sell at zacks investment research kulicke and soffa industries inc klic cut to “sell” at zacks investment research integrated device technology inc idti raised to buy at zacks investment research innocoll holdings’ nasdaqinnl hold rating reiterated at fbr  co polaris venture management co v llc decreases position in ocular therapeutix inc ocul posted by harper lund on jul th   no comments polaris venture management co v llc reduced its stake in shares of ocular therapeutix inc nasdaqocul by  during the first quarter according to its most recent disclosure with the sec the firm owned  shares of the biopharmaceutical company’s stock after selling  shares during the period ocular therapeutix makes up about  of polaris venture management co v llc’s investment portfolio making the stock its th largest position polaris venture management co v llc owned approximately  of ocular therapeutix worth  at the end of the most recent quarter other hedge funds and other institutional investors also recently modified their holdings of the company american international group inc boosted its stake in shares of ocular therapeutix by  in the first quarter american international group inc now owns  shares of the biopharmaceutical company’s stock worth  after buying an additional  shares in the last quarter highbridge capital management llc bought a new position in shares of ocular therapeutix during the first quarter worth about  janney montgomery scott llc acquired a new position in shares of ocular therapeutix during the first quarter worth  ellington management group llc increased its position in shares of ocular therapeutix by  in the fourth quarter ellington management group llc now owns  shares of the biopharmaceutical company’s stock worth  after buying an additional  shares in the last quarter finally trexquant investment lp purchased a new stake in shares of ocular therapeutix during the fourth quarter valued at approximately  institutional investors and hedge funds own  of the company’s stock get ocular therapeutix inc alerts ocular therapeutix inc nasdaqocul opened at  on friday the stock has a  day moving average price of  and a day moving average price of  the company’s market capitalization is  million ocular therapeutix inc has a month low of  and a month high of  ocular therapeutix also saw unusually large options trading activity on thursday investors bought  call options on the company this represents an increase of approximately  compared to the average daily volume of  call options ocular therapeutix nasdaqocul last announced its quarterly earnings data on friday may th the biopharmaceutical company reported  eps for the quarter missing the zacks’ consensus estimate of  by  the firm had revenue of  million for the quarter compared to analysts’ expectations of  million ocular therapeutix had a negative return on equity of  and a negative net margin of  during the same quarter in the previous year the company posted  eps equities analysts predict that ocular therapeutix inc will post  eps for the current fiscal year trademark violation warning this report was reported by chaffey breeze and is the property of of chaffey breeze if you are viewing this report on another domain it was illegally stolen and reposted in violation of united states  international copyright  trademark legislation the correct version of this report can be viewed at httpswwwchaffeybreezecompolarisventuremanagementcovllclowerspositioninoculartherapeutixincoculupdatedupdatedhtml ocul has been the subject of a number of recent analyst reports cantor fitzgerald set a  target price on ocular therapeutix and gave the stock a “buy” rating in a research report on saturday march th cowen and company reiterated an “outperform” rating and issued a  price target on shares of ocular therapeutix in a report on monday march th zacks investment research cut ocular therapeutix from a “hold” rating to a “sell” rating in a report on thursday march th finally btig research restated a “buy” rating and issued a  price target on shares of ocular therapeutix in a research note on tuesday march st four analysts have rated the stock with a hold rating and four have assigned a buy rating to the stock ocular therapeutix has an average rating of “buy” and an average price target of  ocular therapeutix company profile ocular therapeutix inc is a biopharmaceutical company the company is focused on the development and commercialization of therapies for diseases and conditions of the eye using its hydrogel platform technology the company’s bioresorbable hydrogel based product candidates are designed to provide sustained delivery of therapeutic agents to the eye receive news  ratings for ocular therapeutix inc daily  enter your email address below to receive a concise daily summary of the latest news and analysts ratings for ocular therapeutix inc and related companies with marketbeatcoms free daily email newsletter latest news leave a reply click here to cancel reply name required mail will not be published required website polaris venture management company  v llc ratings  rankings by symmetric home about pricing login polaris venture management company  v llc register for more polaris venture overview polaris venture management company  v llc is an investment advisor the managers has disclosed holdings from  to  unlock position crowdedness turnover  concentration polaris venture stockalpha  top  yr stockalpha register for more fundamental  technical factor exposure market cap beta volatility momentum m momentum m momentum m pricebook priceearnings pricecash flow dividend yield sales growth earnings growth roe roa roc ebidta margin debtassets hedge fund crowding polaris venture since last filing return details ticker size sector stock move stockalpha attribution days to liquidate trade crowdedness selb  health     pulm  health     unlock positions and returns details × register to unlock unlock profile and also get manager positions and return details position crowdedness turnover  concentration manager performance estimates top stock pickers report we take your privacy seriously your information will never be shared with any third party × download pdf report your requested report is being generated and will be emailed to you when ready if you do not receive the report please check your spam folder email infosymmetricio or call  featured in polaris venture founders and key employees name title in position since polaris venture brokers custodians auditors and administrators type company polaris venture investment strategy unlock full investment process description polaris venture portfolio concentration unlock portfolio concentration polaris venture location polaris venture contact information phone number null fax number null website null read recent symmetric reports disclaimer the information contained herein  is proprietary to symmetric andor its content providers  may not be copied or distributed and  is not warranted to be accurate complete or timely neither symmetric nor its content providers are responsible for any damages or losses arising from any use of this information past performance and skill metrics are no guarantee of future results symmetric symmetricio and the symmetric logo are marks of symmetric inc read our privacy policy here read our terms of use here path a bizapediacom  human validation companiespeopleproductsservicestrademarksaddressesphone book our system has detected a high number of page requests from your ip address please prove to us that you are a human to continue using our website please send me to the search subscription offer page after i successfully answer the word challenge bizapediapro searchperform unlimited searches via ouradvanced search form withbizapedia pro searchfind out more bizapediapro databuild custom data listsfor one or many stateswith bizapedia pro datafind out more  copyright   · bizapediacom · all rights reservedblogpro searchpro apicontact usterms of useprivacy policysitemapdesktop version technology  polaris partners technology strategy investing in transformative technology and innovative business models where we have deep experience and success saas applications  cloud infrastructure  data sciences  marketplaces  healthcare technology partnership stories we invest throughout the company life cycle – from the earliest creation through profitability – working closely with our teams to reach their goals click below for some of those stories creation expansion later stage creationimprivata from prior to our founding through our ipo polaris has been by our side every step of the way through thick and thin and everything inbetween their commitment has been crucial to our ability to make difficult smart crisp decisions which have enabled us to build critical business value for our customers important leadership within our industry a trulyspecial place for our workforce and a  valuable company for our shareholders in our early days polaris helped us attract worldclass talent at every level of our team as well as to our board they worked their networks and opened up doors to vital business and technology relationships they understood what it meant to be partners mentors constructive critics and central contributors to our strategies to serve a rapidlytransforming healthcare market polaris believed in us from the very beginning applied their operating expertise to our business and helped us navigate an uncharted course in our journey they’ve been true partners in every sense of the word – omar hussain ceo imprivata expansioncliqr choosing polaris as an investment partner was an easy decision for me and cliqr the polaris team is a highly seasoned partnership with tremendous operational background and experience in technology companies and startups working with such a team that is known to back strong technology plays and knows what it takes to win in the long term as an entrepreneur was a key factor in our motivation to work with polaris within a short period of time we have already seen the fruits of this beyond just the initial investment polaris has been instrumental in opening up their network and introducing us to key prospective hires partners and customers above all the mentoring and coaching i have received to help scale a very rapidly growing company in a very exciting space – cloud –  has been personally invaluable to me – gaurav manglik ceo cliqr later stagestrata health we chose polaris as strata health’s partner because they invested in our relationship long before any funding took place  the twoway dialogue that evolved over the course of three years coupled with their proven expertise in saas healthcare solutions fostered a strong sense of trust integrity and mutual respect which is often hard to find in this business since the polaris investment many new doors have opened for strata in terms of markets clients and industry dialogue the have helped us in many ways including recruiting strong new board members introducing us to customer prospects and helping us build out our development team the board has become more strategic in driving our business towards key milestones and the culture of collaboration is accelerating the realization of strata’s global vision  our decision to partner with polaris was the absolute right one and the organization and investors will be more successful because of it – don schick ceo strata health solutions realizing the value of partnership m devices supported by logmein’s  network  daily worldwide web traffic on akamai servers  us mutual fund assets flowing through confluence platform  worldwide internet content created by wordpress b transactions  insidesales predictive cloud contact  polaris partners contact please be in touch   general inquiries media  boston one marina park drive th floorboston ma  san francisco one letterman drive building c rd floor the presidio of san francisco san francisco ca  dublin tribal building top floor  south william streety dublin  ireland internship  polaris partners irishamerican internship program polaris partners is seeking an irish intern for the summer of  to work in our boston office for  weeks time this opportunity is a paid internship with polaris covering visa and travel costs to and from the united states what the experience will include deal sourcing  performing market intelligence research to source exciting and interesting investment opportunities deal execution assisting the team in performing due diligence on deals being executed portfolio support assisting with ad hoc tasks for our portfolio companies relationship building attending boston tech events  supporting the firm’s partners in ad hoc opportunities what we are looking for genuine interest in technology tremendous intellectual curiosity and ability to aggressively pursue compelling investment opportunities independent selfstarter with strong work ethic demonstrated interest in and ability to understand market dynamics competitive strategies and business operations strong written and oral communication skills quantitative and analytical proficiency comfort interacting with senior investment professionals basic accounting financial and excel skills are a plus how to apply we are asking candidates to supply both a cv and a short video of   minutes explaining why you are pursuing this opportunity the application deadline is february    we can’t wait to hear from you apply now home page  polaris partners partnership our true north building relationships with technology  healthcare visionaries across all stages having extensive operating experience with scaling companies polaris gets it and they have our back  which means everything to us as we grow exponentially dave elkington chairman ceo and cofounder of insidesalescom the polaris team not only creates great companies that change the world but they go out of their way to treat everyone fairly  founders employees and other investors  its been a privilege to work with them  dr bob langer cofounder of  polarisbacked companies polaris invested more than capital in cardlytics they provided introductions and counsel to our business which helped turn our vision of connecting banks and advertisers in unprecedented fashion into a reality  lynne laube president and cofounder of cardlytics in a complex industry where opportunities to innovate abound having trusted partners like those at polaris who can put their fingers on the essential issues that really matter makes all the difference  tillman gerngross ceo adimab polaris has a unique ability to see around corners they were among the first investors to recognize the transformative potential of our freemium product approach that support was integral to our long term success michael simon ceo logmein the polaris team consistently brings to the table a combination of creativity vision integrity and commitment to develop important companies that really break boundaries katrine bosley ceo of editas medicine ‹ › backing extraordinary leaders who choose to partner with us again and again  years of partnership polaris repeat entrepreneurs raising the bar on what it means to be an exceptional partner  years of operating and investing experience polaris team realizing the value of partnership k jobs created b market value of polarisbacked companies  repeat entrepreneurs  companies funded b assets under management latest news  by healthcare design magazine silver oaks hospital to build new behavioral health hospital  by venture capital access online floqast raises  million to accelerate company growth and expand adoption of its close management software  by endpoints news from biogen’s buy side to biotech ceo josh mandelbrehm joins the polaris family as a serial entrepreneur in the making all news latest posts  by dave barrett introducing polaris partners viii for technology and healthcare entrepreneurs  by dave barrett hacking growth  by brendan hannigan twistlock leading application container security all posts latest tweets silver oaks hospital to build new behavioral health hospital  hcd magazine sharesbuyde floqast raises  million to accelerate company growth and expand adoption of its close management software businesswirecomnewshome… from biogen’s buy side to biotech ceo josh mandelbrehm joins the polaris family as a serial entrepreneur i   endptscomfrombiogensb… all tweets locations boston one marina park drive th floor boston ma  san francisco one letterman drive rd floor the presidio san francisco ca  dublin tribal building top floor  south william street dublin  ireland   polaris venture management co v llc  ceo founder businessman  profile directorpedianet  list of ceos founders board members and company directors polaris venture management co v llc check out list of companies and businesses related to polaris venture management co v llc find out polaris venture management co v llc address and contact details view other people related to polaris venture management co v llc  coworkers colleagues companions etc address  winter street  suite  waltham  ma companies related to polaris venture management co v llc cikcompany namepositioncompany addressinternet brands inc n sepulveda boulevard th floor el segundo atyr pharma inc owner  john hopkins court ste  san diego selecta biosciences inc owner  arsenal way watertown genocea biosciences inc owner  acorn park drive cambridge kala pharmaceuticals inc beaver street suite  waltham t biosystems inc hartwell avenue lexington pulmatrix inc hayden avenue suite  lexington  polaris venture management co v llc on the web persons related to polaris venture management co v llc  internet brands incnamepositioncitywilliam allen beasleydirector menlo parkwilliam allen beasleymenlo parkrobert n briscoel segundorobert n briscochief executive officer el segundodebra s domeyerchief technology officer el segundojonathan a flintwalthamscott a friedmanchief financial officer el segundokenneth b gilmanstamfordkenneth b gilmandirector el segundomarcia goodsteindirector pasadenagerald greenwalddirector aspenwilliam grossdirector pasadenawilliam grossdirector pasadenaalexander e hansenchief financial officer el segundocharles e hooverchief marketing officer el segundoidealab owner pasadenaidealab holdings llc owner pasadenaterrance mcguirewalthammartin r melonedirector calabasashoward l morgandirector burlingtonhoward l morgandirector burlingtonlisa e moritachief operating officer el segundoroger s penskedirector bloomfield hillsroger s penskedirector bloomfield hillspolaris venture partners entrepreneurs fund v lpwalthampolaris venture partners founders fund v lpwalthampolaris venture partners special founders fund v lpwalthampolaris venture partners v lpwalthamjoseph rosenblumchief technology officer el segundoalan g spoonwalthamjames r ukropinajames r ukropinadirector el segundob lynn walshexecutive vice president el segundopersons related to polaris venture management co v llc  atyr pharma incnamepositioncitysrinivas akkarajudirector srinivas akkarajusan diegoalta partners management viii llcsan franciscoalta partners viii lp owner san franciscoashraf amanullahvice president manufacturing san diegonashat amirsan diegomelissa a ashlocksee remarks san diegokelly blackburnvp clinical affairs san diegostan blackburnacting chief financial officer san diegojames c blairdirector princetonjohn t blakevice president finance san diegofarah champsisan franciscofrederic chereaupresident  coo san diegochp ii lp owner princetonchp ii management llcprincetonholly d chrzanowskisee remarks san diegojohn k clarkedirector princetontimothy p coughlindirector san diegoandrew cubittvp product protection san diegoweiner davidsan diegodeerfield capital lp et alnew yorkmanagement co ny deerfielddeerfield mgmt iii lpnew yorkdeerfield private design fund iii lpnew yorkdeerfield special situations fund lpnew yorkassociates domainprincetondomain partners viii lp owner princetonbrian h doveydp viii associates lp owner bostonpenhoet edsan diegokathryn e falbergdirector rockvillejames e flynn owner new yorkchereau fredericsan diegomark alan goldbergdirector needhammarcy grahamsee remarks san diegobrian k halakprincetonjeffrey s hatfielddirector san diegojames healybrisbanebrandon h hullprincetonblair jamessan diegodaniel janneysan franciscomendlein johnsan diegoclarke johnsan diegokim p kamdarprincetonfalberg kathrynsan diegodavid john kingsee remarks san diegonancy kruegervp legal affairs san diegogrove matsuokasee remarks san diegojohn c mckewvp research san diegoanand mehramenlo parkjohn mendleinceo and director toronto canada mjhamir nashatdirector san diegoguy p nohrasan franciscojohn joseph parkprincetonschimmel paulsan diegopolaris venture partners entrepreneurs fund v lpwalthampolaris venture partners founders fund v lpwalthampolaris venture partners special founders fund v lpwalthampolaris venture partners v lpwalthammichael powellfred ramsdellvp immunology san diegosanuj k ravindranchief business officer san diegopaul schimmeldirector cambridgekathleen k schoemakerprincetonsanjay shuklachief medical officer san diegosofinnova management ix llcmenlo parksofinnova venture partners ix lp owner menlo parkjesse i treuprincetonnicole vitullorichmonddavid m weinerchief medical officer san diegopersons related to polaris venture management co v llc  selecta biosciences incnamepositioncitydavid abrahamgc and corporate secretary watertownnoubar afeyanlexingtonnashat amirwatertownnashat amirwatertownnashat amirwatertownsallin aymericwatertownsallin aymericwatertownsallin aymericwatertowntimothy c barabedirector woburngordon carlwatertowngordon carlwatertowngordon carlwatertownwerner cautreelspresident and ceo woburndouglas colewatertownabraham davidwatertownabraham davidwatertownsiewers davidwatertownsiewers davidwatertownsiewers davidwatertowncole douglaswatertownsands earlwatertownsands earlwatertownkania jr edwinwatertownkania jr edwinwatertownomid farokhzaddirector cambridgeflagship ventures  general partner llccambridgeflagship ventures fund  lp owner cambridgesiber georgewatertownsiber georgewatertowncarl l gordondirector new yorkpeter barton huttdirector irvinesamuel d isalylloyd p johnstoncoo  senior vp rd watertownedwin m kania jrdirector cambridgepeter kellerchief business officer watertowntakashi kei kishimotochief scientific officer watertownrobert langerleukon investments lpchestnut hillshaydullina leysanwatertownjohnston lloydwatertownjohnston lloydwatertownlimited partnership nanodimensiongrand caymannanodimension management ltd owner grand caymanamir nashatdirector san diegofarokhzad omidwatertownfarokhzad omidwatertownfarokhzad omidwatertownorbimed advisors llcdirector orbimed capital gp iii llcnew yorkosage partners llcbala cynwydosage university gp ii lpbala cynwydosage university partners ii lp owner bala cynwydzenner patrickwatertownhutt peterwatertownhutt peterwatertownhutt peterwatertownkeller peterwatertownkeller peterwatertownpolaris venture partners entrepreneurs fund v lpwalthampolaris venture partners founders fund v lpwalthampolaris venture partners special founders fund v lpwalthampolaris venture partners v lpwalthambratzler robertwatertownlanger robertwatertownlanger robertwatertownlanger jr robertwatertownrusnano owner moscowaymeric sallindirector watertownearl sandschief medical officer watertownselecta rkfn ltdmoscowleysan shaydullinawatertowndavid siewerscfo and treasurer watertowntimothy a springerdirector chestnut hillkishimoto takashiwatertownkishimoto takashiwatertowntas partners llcdirector chestnut hillbarabe timothywatertownspringer timothywatertownandrian ulrich vonwatertowncapital ibf netherlands bv vtb owner moscowcautreels wernerwatertowncautreels wernerwatertowncautreels wernerwatertownudaltsov yuriywatertownudaltsov yuriywatertownpatrick j zennerdirector persons related to polaris venture management co v llc  genocea biosciences incnamepositioncityxavier asishcambridgekenneth batedirector cambridgekenneth batedirector cambridgekevin bittermandirector walthamkatrine bosleydirector cambridgewilliam d clarkpresident and ceo rockvillewilliam d clarkpresident and ceo cambridgewilliam d clarkpresident and ceo cambridgeronald harold wilfred cooperdirector cambridgeeinhorn daltoncambridgerobert e farrell jrvp of finance  administration cambridgejessica baker flechtnerchief scientific officer cambridgejessica baker flechtnersr vp of research cambridgesiber georgecambridgesiber georgecambridgesimeon georgedirector conshohockenpaul giannascavp of development cambridgepaul giannascavp of development cambridgeplc glaxosmithkline brentford middlesexseth v hetheringtonchief medical officer alpharettaseth v hetheringtoncambridgeseth v hetheringtonchief medical officer cambridgemichael j higginsdirector cambridgeeric s hoffmanchief business officer cambridgestephen j hoffmandirector carlislestephen j hoffmandirector walthamflechtner jessicacambridgeflechtner jessicacambridgejohnson  johnson owner new brunswickjohnson  johnson development corp et alnew brunswickbosley katrinecambridgebitterman kevincambridgebitterman kevincambridgechen leoncambridgelux capital management llc new yorklux venture associates ii llcnew yorklux venture partners ii lpnew yorklux ventures ii lpnew yorklux ventures ii sidecar ii llcnew yorklux ventures ii sidecar lpnew yorkhoward mayerdirector cambridgegiannasca paulcambridgegiannasca paulcambridgepolaris venture partners entrepreneurs fund v lpwalthampolaris venture partners entrepreneurs fund v lpwalthampolaris venture partners entrepreneurs fund v lpwalthampolaris venture partners founders fund v lpwalthampolaris venture partners founders fund v lpwalthampolaris venture partners founders fund v lpwalthampolaris venture partners special founders fund v lpwalthampolaris venture partners special founders fund v lpwalthampolaris venture partners special founders fund v lpwalthampolaris venture partners v lpwalthampolaris venture partners v lpwalthampolaris venture partners v lpwalthamjonathan poolechief financial officer cambridgevenkataramani ravicambridgefarrell jr robertcambridgefarrell jr robertcambridgepaull robertcambridgepaull robertcambridgehetherington sethcambridgegeorge siberdirector new yorkgeorge simeoncambridgegeorge simeoncambridgehoffman stephencambridgehoffman stevecambridgeravichandran venkataramanicambridgeclark williamcambridgeclark williamcambridgepersons related to polaris venture management co v llc  kala pharmaceuticals incnamepositioncityfranz andreawalthamgilly bernardwalthamgilly bernardwalthamkim brazzellchief medical officer durhamcaxton corpprincetoncdk associates llc owner princetonmcdermott charleswalthamhongming chenchief scientific officer walthamyu chenwalthamcvf llcpatrick g enrightburlingamegrunberg gregwalthamgregory grunbergdirector walthampfefer guillaumewalthampfefer guillaumewalthamhadley harbor master investors cayman lp owner bostonjustin haneswalthampaulina hilldirector walthamchen hongmingwalthamchen hongmingwalthamrosen howardwalthamsamuel d isalymark t iwickichief executive officer marlboroughhanes justinbaltimorehanes justinwalthamhanes justinwalthamwagner karenwalthambitterman kevinwalthambitterman kevinwalthambitterman kevinwalthampojasek kevinwalthambrazzell kimwalthampeter kolchinskybostonbruce kovnernew yorkrobert langerdirector michele larussawalthamlongitude capital partners ii llc owner menlo parklongitude venture partners ii lpmenlo parklux capital management llcnew yorklux venture associates ii llcnew yorklux venture partners ii lpnew yorklux ventures ii lpnew yorklux ventures ii sidecar lpnew yorkiwicki markwalthamcharles douglas mcdermottwalthamorbimed advisors llc owner orbimed capital gp vi llcnew yorkrobert bradley paulldirector walthamcourossi peterwalthampolaris venture partners entrepreneurs fund v lpwalthampolaris venture partners founders fund v lpwalthampolaris venture partners special founders fund v lpwalthampolaris venture partners v lpwalthamra capital biotech fund lpbostonra capital management llcdirector bostonshah rajeevwalthammary reumuthchief financial officer walthamlanger robertwalthamlanger robertwalthamlanger robertwalthamlanger robertnewtonpaull robertnew yorkpaull robertwalthampaull robertwalthampaull robertwalthamtepper robertwalthamtepper robertwalthamtepper robertwalthamhoward b rosendirector mountain viewrajeev m shahdirector bostonbakker juliet tammenomsmenlo parkrobert i tepperdirector cambridgebiofund i fcr ysiosbarcelonapersons related to polaris venture management co v llc  t biosystems incnamepositioncityjones adrianlexingtonnoubar afeyanlexingtonnoubar afeyancambridgeaisling capital iii lp owner new yorkaisling capital iii lp owner new yorkaisling capital iii lpnew yorkaisling capital partners iii llcnew yorkaisling capital partners iii llcnew yorkaisling capital partners iii llcnew yorkaisling capital partners iii lpnew yorkaisling capital partners iii lpnew yorkaisling capital partners iii lpnew yorkcrane alanlexingtoncrane alancambridgecrane alanlexingtonjoshua h bilenkerdirector warrenbridge street  holdings lpnew yorkbridge street  lpnew yorkbridge street  offshore lpnew yorkbridge street opportunity advisors llcnew yorkbroad street principal investments llcnew yorkbroad street principal investments llcnew yorkbroad street principal investments llcnew yorkcanon inctokyocanon usa incmelvillethomas j carelladirector new yorkthomas j carella new yorkmaurice l castonguaychief financial officer redwood citymichael j cimadirector lexingtonmichael j cimadirector lexingtonalan l cranedirector cambridgejohn w cummingdirector bedfordjohn w cumminglexingtonelsbree davidlexingtonharding davidlexingtondarlene m deptulahickssvp  chief financial officer wakefieldrahul dhandasvp of corporate development lexingtonlevinson dougcambridgesteve elmschestersteve elmsnew yorksteve elmsnew yorkdavid b elsbreedirector cambridgedavid b elsbreelexingtondavid b elsbreedirector lexingtonflagship ventures fund  l pcambridgeflagship ventures fund  l p owner cambridgeflagship ventures fund iv general partner llccambridgeflagship ventures fund iv general partner llccambridgeflagship ventures fund iv lpcambridgeflagship ventures fund iv lpcambridgeflagship ventures general partner llccambridgeflagship ventures general partner llccambridgemichael terrence gibbsgeneral counsel lexingtongoldman sachs  cogoldman sachs  conew yorkgoldman sachs group inc goldman sachs group inc new yorkdavid hardingchief commercial officer marlboroughwilcox harrylexingtonwilcox harrylexingtonwiesen jeffreybostonspadoro phd joannelexingtonmcdonough johncambridgemcdonough johnlexingtonmcdonough johnlexingtonmcdonough johnlexingtoncumming johnlexingtonadrian m jones new yorkmarc r joneslexingtonbilenker joshlexingtonbilenker joshlexingtonbilenker md joshlexingtonsarah o kalilchief operating officer lexingtonedwin m kania jredwin m kania jrcambridgestanley lapidusdirector lexingtonstanley n lapidusdirector marlboroughstanley n lapiduslexingtonseymour liebmandirector west hempsteadthomas j lowerychief scientific officer lexingtonshawn lynchchief financial officer lexingtonmbd  holdings lpnew yorkmbd  lpnew yorkmbd  offshore lpnew yorkmbd advisors llc new yorkjohn mcdonoughpresident and ceo lexingtonpfaller md michaellexingtoncima michaelwest newtoncima michaellexingtoncima michaellexingtoncima phd michaellexingtongibbs esq michaellexingtongreeley michaellexingtongreeley michaelcambridgegreeley michaellexingtonmichael a pfallerchief medical officer lexingtonpolaris venture partners entrepreneurs fund v lpwalthampolaris venture partners entrepreneurs fund v lpwalthampolaris venture partners entrepreneurs fund v lpwalthampolaris venture partners founders fund v lpwalthampolaris venture partners founders fund v lpwalthampolaris venture partners founders fund v lpwalthampolaris venture partners special founders fund v lpwalthampolaris venture partners special founders fund v lpwalthampolaris venture partners special founders fund v lpwalthampolaris venture partners v lp owner walthampolaris venture partners v lp owner walthampolaris venture partners v lpwalthamdennis j purcellnew yorkdennis j purcellnew yorkdennis j purcellnorristowndhanda rahullexingtonlanger robertwest newtonlanger robertlexingtonlanger robertlexingtonandrew n schiffnew yorkandrew n schiffnew yorkdr drew schiffnew yorkliebman seymourlexingtonlynch shawnlexingtonjoanne spadorochief operations officer lexingtonfeld stacylexingtonfeld stacylexingtonlapidus stancambridgelapidus stanlexingtonlapidus stanlexingtonlapidus stanleylexingtonscampini stevenlexingtonlowery thomaslexingtonlowery thomaslexingtoncarella tjlexingtonlowery phd tomlexingtonharry w wilcoxdirector marlboroughharry w wilcoxcambridgepersons related to polaris venture management co v llc  pulmatrix incnamepositioncityakihisa akaodirector petalumaakao akihisasanta rosahojabr alimiceo and chief science officer santa rosaarch venture fund vii lpchicagoarch venture partners vii lpchicagoarch venture partners vii llcchicagoclinton bybeechicagorobert w clarkechief executive officer lexingtonrichard k conleydirector petalumarichard k conleydirector santa rosakeith crandellchicagohava davidlexingtonmaki davidlexingtonwilliam e dukechief financial officer lexingtonjonathan a flintwalthamgregory m frenchdirector petalumagregory m frenchdirector santa rosasteven gillisdirector seattlekurt gravesdirector cambridgefrench gregorysanta rosafrench gregorysanta rosasameer harishchief financial officer santa rosadavid l havachief scientific officer lexingtonmichael j higginsdirector cambridgealimi hojabrsanta rosaalimi hojabrsanta rosamark t iwickidirector marlboroughgraves kurtlexingtondavid makidirector lexingtonterrance mcguiredirector walthamhiggins michaellexingtonamit munshidirector bostonrobert nelsenoculus innovative sciences inc owner petaluma oculus innovative sciences incpetalumapolaris venture management co iv llcwalthampolaris venture partners entrepreneurs fund iv lpwalthampolaris venture partners entrepreneurs fund v lpwalthampolaris venture partners founders fund v lpwalthampolaris venture partners iv lpwalthampolaris venture partners special founders fund v lpwalthampolaris venture partners v lpwalthamteofilo david raadchief business officer lexingtonconley richardsanta rosaconley richardsanta rosaclarke robertlexingtonscott m rocklagedirector lincolnharish sameersanta rosaharish sameersanta rosarocklage scottlexingtonmatthew l shermandirector cambridgegillis stevenlexingtonmcguire terrancelexingtonduke williamlexington potentially same personnamecitycountrypolaris venture management co v llcwalthammapolaris venture management co v llcwalthammapolaris venture management co v llcwalthammapolaris venture management co v llcwalthammapolaris venture management co v llcwalthammapolaris venture management co v llcwalthamma portfolio  polaris partners portfolio our companies share our passion for innovation in disruptive technologies in ground breaking science in transformative business models get to know them active technology companies saas applications cloud infrastructure data sciences marketplaces healthcare technology healthcare companies biotechnology diagnostics  devices healthcare technology healthcare services  products earlyexpansion later alumni ipos acquisitions active technology technology companies saas applications cloud infrastructure data sciences marketplaces healthcare technology healthcare healthcare companies biotechnology diagnostics and devices healthcare technology healthcare services  products stage earlyexpansion later alumni ipos acquisitions technology  all technology companies technology  saas applications technology  cloud infrastructure technology  data sciences technology  marketplaces technology  healthcare technology healthcare  all healthcare companies healthcare  biotechnology platforms healthcare  diagnostics and devices healthcare  healthcare technology healthcare  healthcare services  products stage  earlyexpansion stage  later healthcare  polaris partners healthcare strategy investing in novel therapeutics medical technologies and innovative delivery platforms that meet the critical needs of patients worldwide biotechnology  medical devices  diagnostics  healthcare technology  healthcare services  products partnership stories we invest throughout the company life cycle – from the earliest creation through profitability – working closely with our teams to help reach their goals click below for some of those stories creation expansion later stage creationvisterra polaris has been a visionary partner in the founding and building of visterra working with our scientific team on the initial concept in the mit labs forming the company inlicensing the ip hiring our first employees and serving as interim leadership in those early days  the firm has not only been our largest shareholder but also a great champion supporting a bold vision leading our board of directors as we achieved each milestone and addressed every opportunity in building a platform that redefines the targeting of infectious disease  as a result of our partnership visterra has a strong investor syndicate that understands our science and our business and a management team that works exceptionally well together in breaking new ground  at each point where the company was ready to move to the next phase of development the polaris team has been there as an anchor and will continue to be as we seek to help millions of patients worldwide – brian pereira ceo visterra expansionreceptos after raising a successful series a investment in  we worked closely with polaris to galvanize our series b round in  which was a challenging fundraising environment globally during this time polaris came to the table recognizing the opportunity from both a scientific and business perspective and throwing support behind our team it was a critical inflection point in our evolution and polaris was there for us when others were not   once on board as an investor polaris was a “thought partner” subscribing to our collective belief that the essence of strategy is choice  together throughout our growth we explored many divergent paths before converging on the right one  this relationship allowed us to assess different options at the board level while supporting the team emotionally spiritually and strategically  the result  receptos was able to hit or exceed our milestones and go public at a crucial time while developing important therapies to treat patients with debilitating diseases polaris played an important role in this success – faheem hasnain president  ceo receptos  later stageascend we were was a single bed psychiatric hospital looking for an investment partner who believed in our model to deliver specialty behavioral health programs to patients in underserved markets  polaris quickly recognized ascend’s opportunity in the  billion mental health arena where demand was outstripping supply  i chose to partner with them because of their commitment to our innovative services business model  it was a smart move  polaris stepped up quickly at a time when our business was accelerating but the capital markets were challenged  our behavioral health platform became validated with recognition of our programs for women youth active military affected by combat and patients with cooccurring disorders with polaris as our largest investor we expanded ascend’s hospital chain to  states our patient bed count went up more than  times and we generated  million in annual revenue and  million in profits — all in  years  at the time of our sale to universal health services ascend was the largest private psychiatric hospital provider in the country  within months of the transaction i chose polaris as my lead investor in us healthvest where we continue to do important work on behalf of psychiatric patients – dr richard kresch ceo ascend  us healthvest realizing the value of partnership m patient lives touched  years of investment experience  companies spun out of academia  diseases  conditions treated  new medicines brought to market polaris venture management co v llc  genocea biosciences insider transactions  tipranks go prologin  sign up follow✓get real time transactionsinsider detailspolaris venture management co v llcgenocea biosciences gncaten percent ownerranked  out of  insiders on tiprankspolaris venture management co v llcs performanceprofitable transactions out of  profitable transactionsaverage returnaverage return per transactioneach transaction is measured over a  year months month period and compared to no benchmarksp sectorhow are insiders ranked insider holdings  genocea biosciences gnca  fate therapeutics fate  cerulean pharma ceru  trevena inc trvn  ocular therapeutix oculmsee the top stocks by insiders  insider rolesgenocea biosciences gnca ten percent ownerfate therapeutics fate ten percent ownercerulean pharma ceru ten percent ownertrevena inc trvn ten percent ownerocular therapeutix ocul ten percent ownersee the top  corporate insiders  most profitable insider tradestock ocular therapeutix ocultransaction type informative selldates feb    feb  gain see the latest stocks traded by insiders  polaris venture management co v llcs trading historybased on form  follow✓get real time transactionscompany nameinsider positionholding valuelast transactionlast transaction amountlast transaction dategncagenocea biosciencesten percent ownerinformative selljun  oculocular therapeutixten percent ownerinformative sellfeb  trvntrevena incten percent ownerinformative sellaug  cerucerulean pharmaten percent ownerinformative buyapr  fatefate therapeuticsten percent ownerinformative buyoct  bindqbind therapeuticsten percent ownerinformative buysep  see all insider trading from today you may also likemeet our smart portfolio see what top analysts say about your stocksget a breakdown of the different strategies based on detected insider trading activityfind the best performing analyst in each sector follow them so you never miss a recommendationrelated linkshow can i benefit from insider trading see the top  corporate insiders go to hot stocks by insiders find which stocks insiders traded today become a tipranks memberget the best investing tips  hacks straight to your emailfree membershipsubmitinsider trading daily newsletterprofessional daytrading strategy based on predictive insider transactionsannual return learn more powered by polaris team  polaris partners team we strive to be the kinds of partners who we would want by our side show all healthcare technology operations show all  healthcare  technology  operations mark augenstern mark augenstern associate dave barrett dave barrett managing partner mary blair mary blair chief financial officer brian chee brian chee managing partner alan crane alan crane partner entrepreneur max eisenberg max eisenberg general counsel jon flint jon flint founding partner brendan hannigan brendan hannigan venture partner michael higgins michael higgins entrepreneur in residence paulina hill paulina hill principal pat kinsel pat kinsel venture partner dan lombard dan lombard principal josh mandelbrehm josh mandelbrehm entrepreneur in residence terry mcguire terry mcguire founding partner amir nashat amir nashat managing partner noel ruane noel ruane venture partner connor ryan connor ryan associate amy schulman amy schulman venture partner gary swart gary swart partner bryce youngren bryce youngren managing partner ﻿ ocular therapeutix inc ocul expected to post earnings of  per share  chaffey breeze daily ratings  news for ocular therapeutix inc complete the form below to receive the latest headlines and analysts recommendationsfor ocular therapeutix inc with our free daily email newsletter follow chaffeybreeze recent posts lakeland financial corporation lkfn to issue  quarterly dividend healthcare trust of america inc hta forecasted to earn q  earnings of  per share richelieu hardware ltd tserch declares quarterly dividend of   million in sales expected for six flags entertainment corporation new six this quarter easterly government properties inc dea to post q  earnings of  per share jefferies group forecasts eagle pharmaceuticals inc egrx raised to “hold” at zacks investment research  eps expected for monster beverage corporation nasdaqmnst this quarter zacks analysts expect wr berkley corporation nysewrb will announce quarterly sales of  billion incontact nasdaqsaas and synchronoss technologies sncr financial analysis head to head contrast hhgregg hgg vs cencosud sa cnco reviewing comcast corporation cmcsa and global eagle entertainment nasdaqent ocular therapeutix inc ocul expected to post earnings of  per share gentex corporation gntx issues quarterly earnings results misses estimates by  eps financial analysis penn west petroleum obe versus resolute energy corporation ren zacks investment research upgrades webcom group inc nasdaqweb to “buy” marks and spencer group plc lonmks stock rating reaffirmed by investec umb financial corporation nasdaqumbf upgraded by zacks investment research to “buy” morgan stanley reaffirms equal weight rating for calpine corporation nysecpn comparing medallion financial corp mfin and main street capital corporation nysemain contrasting flir systems flir and napco security technologies nssc ocular therapeutix inc ocul expected to post earnings of  per share posted by charlotte bryant on jul rd   no comments equities analysts expect that ocular therapeutix inc nasdaqocul will post earnings per share eps of  for the current quarter according to zacks investment research zero analysts have made estimates for ocular therapeutix’s earnings ocular therapeutix posted earnings per share of  in the same quarter last year which suggests a negative year over year growth rate of  the company is scheduled to issue its next earnings results on tuesday august th on average analysts expect that ocular therapeutix will report full year earnings of  per share for the current year with eps estimates ranging from  to  for the next year analysts expect that the firm will report earnings of  per share with eps estimates ranging from  to  zacks’ earnings per share averages are an average based on a survey of sellside research firms that follow ocular therapeutix get ocular therapeutix inc alerts ocular therapeutix nasdaqocul last posted its quarterly earnings data on friday may th the biopharmaceutical company reported  earnings per share for the quarter missing the consensus estimate of  by  the company had revenue of  million during the quarter compared to analyst estimates of  million ocular therapeutix had a negative net margin of  and a negative return on equity of  during the same quarter in the previous year the business posted  eps a number of research analysts have recently commented on ocul shares valuengine raised shares of ocular therapeutix from a “sell” rating to a “hold” rating in a report on tuesday june th btig research cut ocular therapeutix from a “buy” rating to a “neutral” rating in a report on friday may th zacks investment research upgraded ocular therapeutix from a “hold” rating to a “buy” rating and set a  price target on the stock in a report on tuesday may th cantor fitzgerald reiterated an “overweight” rating and issued a  target price on shares of ocular therapeutix in a report on monday may th finally morgan stanley cut ocular therapeutix from an “overweight” rating to an “equal weight” rating and set a  target price on the stock in a report on friday june rd one research analyst has rated the stock with a sell rating three have given a hold rating and four have assigned a buy rating to the company’s stock ocular therapeutix currently has an average rating of “hold” and an average price target of  a number of institutional investors have recently modified their holdings of the stock state street corp boosted its position in shares of ocular therapeutix by  in the fourth quarter state street corp now owns  shares of the biopharmaceutical company’s stock valued at  after buying an additional  shares during the period renaissance technologies llc bought a new position in shares of ocular therapeutix during the fourth quarter valued at  teachers advisors llc boosted its position in shares of ocular therapeutix by  in the fourth quarter teachers advisors llc now owns  shares of the biopharmaceutical company’s stock valued at  after buying an additional  shares during the period berson  corrado investment advisors llc boosted its position in shares of ocular therapeutix by  in the first quarter berson  corrado investment advisors llc now owns  shares of the biopharmaceutical company’s stock valued at  after buying an additional  shares during the period finally columbus circle investors boosted its position in shares of ocular therapeutix by  in the first quarter columbus circle investors now owns  shares of the biopharmaceutical company’s stock valued at  after buying an additional  shares during the period institutional investors and hedge funds own  of the company’s stock ocular therapeutix nasdaq ocul traded down  during midday trading on thursday reaching   shares of the company’s stock traded hands ocular therapeutix has a week low of  and a week high of  the stock has a day moving average of  and a  day moving average of  the company’s market cap is  million illegal activity notice “ocular therapeutix inc ocul expected to post earnings of  per share” was published by chaffey breeze and is owned by of chaffey breeze if you are reading this story on another domain it was copied illegally and republished in violation of united states  international trademark  copyright legislation the legal version of this story can be accessed at httpswwwchaffeybreezecomoculartherapeutixincoculexpectedtopostearningsofpersharehtml about ocular therapeutix ocular therapeutix inc is a biopharmaceutical company the company is focused on the development and commercialization of therapies for diseases and conditions of the eye using its hydrogel platform technology the company’s bioresorbable hydrogel based product candidates are designed to provide sustained delivery of therapeutic agents to the eye get a free copy of the zacks research report on ocular therapeutix ocul for more information about research offerings from zacks investment research visit zackscom receive news  ratings for ocular therapeutix inc daily  enter your email address below to receive a concise daily summary of the latest news and analysts ratings for ocular therapeutix inc and related companies with marketbeatcoms free daily email newsletter latest news leave a reply click here to cancel reply name required mail will not be published required website polaris venture management company  v llc top holdings whalewisdom search all search f filers only search sec filer search stocks only search mgmt inv cos only etfs only search active polaris venture management company  v llc • boston ma how do i update this listing polaris venture management company  v is based out of boston their last reported f filing for q  included  in managed f securities and a top  holdings concentration of  polaris venture management company  vs largest holding is selecta bioscncs with shares held of  whalewisdom has at least  f filings and  insider transactions form  in our database for polaris venture management company  v summary f holdings ind managers dg insider form  download f summary to excel download f summary to excel create email alert × email notification log in or signup to see more advanced email alert options such as selecting any type of sec form multiple filers or classes of filers and much more or to simply have an email sent to you whenever we receive a new f filing from polaris venture management company  v llc enter your email address below and choose submit your email cancel  top buys name change  top sells name change ocul ocular therapetx   f holdings summary stock port selb selecta bioscncs  pulm pulmatrix inc com  gnca genocea bioscnc  fate fate therapeutics inc  ttoo t biosystms inc  see all holdings  f activity market value  million prior market value  million new purchases stocks additional purchases stocks sold out of stocks reduced holdings in stock top  holdings  turnover   turnover alt   time held top quarters time held top quarters time held all quarters  turnover is calculated by taking the  of new holdings initial purchases  the  of positions sold out of not just reduced divided by the total  of holdings for the quarter  alt turnover is calculated by taking either the total mv of new purchases or the mv of securities sold whichever is less divided by the total mv of the fund  f sector allocation over time fund metrics you are limited to the prior  quarters of f filings subscribe to whalewisdom to view all filing data for polaris venture management company  v llc portfolio performance top  equalweighted holdings last updated on  performance for q   performance last  quarters  performance metrics stdev yrs subscription required beta yrs subscription required alpha yrs subscription required max drawdown allyears subscription required annualized perf yrs subscription required batting avg vs sp yrs subscription required sortino yrs subscription required stutzer yrs subscription required treynor yrs subscription required sterling yrs subscription required calmar yrs subscription required information ratio yrs subscription required tracking error  yrs subscription required stdev down yrs subscription required winning months  subscription required losing months  subscription required best  months subscription required worst  months subscription required efficiency ratio yrs subscription required sharpe subscription required stdev sectors subscription required skewness yrs subscription required kurtosis yrs subscription required upside potential yrs subscription required backtester use whalewisdoms backtester tool to test how a hypothetical portfolio would have performed with different investment strategies research one or more filers performance and then optimize their portfolios to match your own investment goals start with one of our predefined groups or create your own view the backtesting whitepaper and the getting started page for additional help take a tour save changes to tracked backtest saving generate report at least one fund must be selected before running a backtest  ending sector allocation quarter to view current combined fdg q  f filings q  f filings q  f filings q  f filings q  f filings q  f filings q  f filings q  f filings q  f filings subscription required q  f filings subscription required q  f filings subscription required q  f filings subscription required q  f filings subscription required refresh advanced export download csv download excel xlsx download tsv click to see additional filters security types shares calls puts principal changes in holdings new position added to position reduced position closed out position no change ranking is in the top minimum  of shares stock ticker is etf yesno refresh edit columns shares are split adjusted × report an error your name optional your email optional error to report or any other commentsrequired cancel click here to report any possible errors with this listing f filings available   fhr subscription required   fhr subscription required   fhr subscription required   fhr subscription required   fhr subscription required   fhr subscription required   fhr subscription required   fhr subscription required   fhr subscription required   fhra subscription required   fhr subscription required   fhra subscription required   fhr subscription required   fhr subscription required   fhr subscription required × csv export module this will schedule a job to export all requested f holdings data for this filer when completed an email will be sent to the email address you specify containing a link to download the zip file of the csv files you requested output type output all f holdings into a single csv file output all f holdings into separate csv files per quarter columns to include filer name stock name stock ticker quarter date type of security current shares held current market value previous shares held previous market value current  of portfolio previous  of portfolio current rank previous rank change in shares type of change sector f quarters to include         email address to send data to cancel schedule export schedule d and g events since  subscription required form   nonderivative insider transactions since  loading elevate your investments try it for free